- Home
- XHG vs TIL Comparison
XHG vs TIL Comparison
Compare XHG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHG
- TIL
- Stock Information
- Founded
- XHG 2012
- TIL 2018
- Country
- XHG China
- TIL United States
- Employees
- XHG N/A
- TIL N/A
- Industry
- XHG
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- XHG
- TIL Health Care
- Exchange
- XHG NYSE
- TIL Nasdaq
- Market Cap
- XHG 83.5M
- TIL 230.1M
- IPO Year
- XHG 2019
- TIL 2021
- Fundamental
- Price
- XHG $1.30
- TIL $23.14
- Analyst Decision
- XHG
- TIL Buy
- Analyst Count
- XHG 0
- TIL 5
- Target Price
- XHG N/A
- TIL $119.00
- AVG Volume (30 Days)
- XHG 134.6K
- TIL 387.8K
- Earning Date
- XHG 07-11-2025
- TIL 08-12-2025
- Dividend Yield
- XHG N/A
- TIL N/A
- EPS Growth
- XHG N/A
- TIL N/A
- EPS
- XHG N/A
- TIL N/A
- Revenue
- XHG $41,110,414.00
- TIL N/A
- Revenue This Year
- XHG N/A
- TIL N/A
- Revenue Next Year
- XHG N/A
- TIL N/A
- P/E Ratio
- XHG N/A
- TIL N/A
- Revenue Growth
- XHG N/A
- TIL N/A
- 52 Week Low
- XHG $1.16
- TIL $9.62
- 52 Week High
- XHG $1,200.00
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- XHG 33.61
- TIL 43.15
- Support Level
- XHG $1.19
- TIL $21.29
- Resistance Level
- XHG $1.52
- TIL $31.67
- Average True Range (ATR)
- XHG 0.15
- TIL 3.95
- MACD
- XHG 0.12
- TIL -1.71
- Stochastic Oscillator
- XHG 31.58
- TIL 8.60
About XHG XCHANGE TEC.INC SPON ADS EACH REP 600000 SHS(POST SPLIT)
XChange Tec Inc, through its subsidiaries operates in insurance agency and insurance technology business. The company specialized in distributing automobile insurance policies at the earlier stage of business and subsequently expanded insurance product portfolio to include other types of insurance including life, health, group accident and other property related insurances. A maximum of the insurance purchased through platform and agency services is of automobile insurance.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.